Gilead's coronavirus antiviral remdesivir gets conditional EU clearance

The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region's first authorized therapy to treat the virus. The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug, produced by Gilead Sciences,...